Telix Successfully Prices Upsized US$600M Convertible Bonds
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Additionally, Telix plans to repurchase a significant portion of its existing convertible bonds as part of its capital management strategy. The settlement of this offering is expected to occur in the near future, subject to customary conditions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Telix Investor Presentation April 2026
- Telix Refinances Convertible Bonds
- Telix and Regeneron Announce Strategic Radiopharma Collaboration
- Regeneron and Telix Announce Strategic Radiopharma Collaboration
- Telix and Regeneron Announce Radiopharma Collaboration
Later from Telix Pharmaceuticals
- ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
- Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
- OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
- TLX101-Px (Pixlumi®) MAA Accepted in Europe
- New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals